Vanguard Group’s SOLAZYME INC COM STK (DE) SZYM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q2 | – | Sell |
-2,698,748
| Closed | -$5.48M | – | 4179 |
|
|
2016
Q1 | $5.48M | Buy |
2,698,748
+28,277
| +1% | +$50.4K | ﹤0.01% | 2915 |
|
|
2015
Q4 | $6.62M | Buy |
2,670,471
+272,183
| +11% | +$807K | ﹤0.01% | 2850 |
|
|
2015
Q3 | $6.24M | Buy |
2,398,288
+155,872
| +7% | +$406K | ﹤0.01% | 2863 |
|
|
2015
Q2 | $7.04M | Buy |
2,242,416
+77,346
| +4% | +$265K | ﹤0.01% | 2850 |
|
|
2015
Q1 | $6.19M | Sell |
2,165,070
-734,574
| -25% | -$1.88M | ﹤0.01% | 2884 |
|
|
2014
Q4 | $7.48M | Sell |
2,899,644
-774,044
| -21% | -$3.39M | ﹤0.01% | 2681 |
|
|
2014
Q3 | $27.4M | Buy |
3,673,688
+513,608
| +16% | +$4.8M | ﹤0.01% | 2089 |
|
|
2014
Q2 | $37.2M | Buy |
3,160,080
+106,760
| +3% | +$1.14M | ﹤0.01% | 1974 |
|
|
2014
Q1 | $35.4M | Buy |
3,053,320
+693,449
| +29% | +$8.16M | ﹤0.01% | 1978 |
|
|
2013
Q4 | $25.7M | Buy |
2,359,871
+287,661
| +14% | +$2.83M | ﹤0.01% | 2080 |
|
|
2013
Q3 | $22.3M | Buy |
2,072,210
+356,670
| +21% | +$4.06M | ﹤0.01% | 2070 |
|
|
2013
Q2 | $20.1M | Buy |
+1,715,540
| New | +$17.1M | ﹤0.01% | 2066 |
|
Vanguard Group's SZYM Position: Q2 2016 in Review
Vanguard Group sold out of SOLAZYME INC COM STK (DE) (SZYM) in Q2 2016, closing a stake of 2,698,748 shares — an estimated $5.48M sold.
Vanguard Group first reported a position in SZYM in Q2 2013 and held it in 12 quarters. The position peaked at $37.2M in Q2 2014. 0 funds tracked by Wall St. Rank hold SZYM as of Q2 2016.
- Vanguard Group reported no remaining SOLAZYME INC COM STK (DE) position as of Q2 2016 after selling out during the quarter.
- Vanguard Group sold 2,698,748 SOLAZYME INC COM STK (DE) shares in Q2 2016, an estimated $5.48M.
- Vanguard Group first reported a position in SOLAZYME INC COM STK (DE) in Q2 2013 and held it in 12 quarters.
- Vanguard Group's SOLAZYME INC COM STK (DE) position peaked at $37.2M in Q2 2014.
- 0 funds tracked by Wall St. Rank held SOLAZYME INC COM STK (DE) as of Q2 2016.
Based on Vanguard Group's 13F filing for Q2 2016, filed 10 Aug 2016.